Related Experiment Videos
Factors predictive of marked decrease in HDL-C by probucol treatment.
A Yashiro1, Y Nakashima, J Segawa
1Second Department of Internal Medicine, University of Occupational and Environmental Health Japan, School of Medicine, Kitakyushu.
Artery
|January 1, 1990
Summary
Probucol effectively lowers LDL-C but can significantly reduce HDL-C. The Apo A-I/HDL-C ratio before treatment predicts this reduction, guiding cautious Probucol administration in hyperlipidemic patients.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Lipid Metabolism
Background:
- Probucol is a lipid-lowering drug known for reducing low-density lipoprotein cholesterol (LDL-C).
- A significant reduction in high-density lipoprotein cholesterol (HDL-C) by Probucol is a concern, as HDL-C is generally considered anti-atherosclerotic.
- Predicting which hyperlipidemic patients will experience a marked decrease in HDL-C during Probucol treatment is crucial for safe administration.
Purpose of the Study:
- To identify pre-administration factors that predict a significant reduction (≥20%) in HDL-C levels in patients treated with Probucol.
- To enable clinicians to anticipate and manage potential adverse effects on HDL-C before initiating Probucol therapy.
Main Methods:
- A study involving 30 patients with type II hypercholesterolemia who received Probucol (250-750 mg/day).
- Linear discriminant function analysis was employed using 12 pre-administration lipid parameters.
- The primary objective was to evaluate predictive values of baseline lipid profiles for post-Probucol HDL-C reduction.
Main Results:
- Twenty-three out of 30 patients (76.7%) exhibited a decrease greater than 20% in HDL-C levels after Probucol administration.
- The Apo A-I/HDL-C ratio before Probucol treatment emerged as the most significant predictor of HDL-C reduction (F = 17.8, P < 0.01).
- A baseline Apo A-I/HDL-C ratio of 5.3 or less accurately predicted a ≥20% decrease in HDL-C with Probucol therapy.
Conclusions:
- The pre-treatment Apo A-I/HDL-C ratio is a valuable biomarker for predicting significant HDL-C reduction in hyperlipidemic patients undergoing Probucol therapy.
- This predictive marker allows for informed clinical decisions and cautious management of Probucol, particularly in patients with a low baseline Apo A-I/HDL-C ratio.